Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P51970
UPID:
NDUA8_HUMAN
Alternative names:
Complex I-19kD; Complex I-PGIV; NADH-ubiquinone oxidoreductase 19 kDa subunit
Alternative UPACC:
P51970; B1AM93; Q9Y6N0
Background:
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 8, also known as Complex I-19kD, Complex I-PGIV, or NADH-ubiquinone oxidoreductase 19 kDa subunit, plays a crucial role in cellular energy production. It serves as an accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), facilitating the transfer of electrons from NADH to the respiratory chain, with ubiquinone as the immediate electron acceptor.
Therapeutic significance:
The protein is implicated in Mitochondrial complex I deficiency, nuclear type 37 (MC1DN37), a condition with symptoms ranging from developmental delay to epilepsy and myopathy. Understanding the role of NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 8 could open doors to potential therapeutic strategies for this and related mitochondrial disorders.